Core Scientific, Inc/tx Form 4 insider transactions

Core Scientific CEO Adam Taylor Sullivan reported the disposition of 23,508 shares of common stock to cover tax obligations from restricted stock unit vesting, alongside a previously acquired 4,912 shares from an in-kind distribution.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, reported the disposition of 8,228 shares of common stock at $17.07 per share to cover tax withholding obligations related to restricted stock unit vesting.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, sold 7,759 shares of common stock to cover tax obligations related to restricted stock unit vesting, while also receiving 7,346 shares from a bankruptcy claims settlement.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, sold 50,000 shares of common stock for approximately $12.31 per share on June 4, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, sold 60,000 shares of common stock for approximately $680,000 under a Rule 10b5-1 trading plan.

Core Scientific, Inc. Director Elizabeth Crain was granted 46,773 restricted stock units (RSUs) as part of her compensation, vesting in full on May 14, 2028.

A recent SEC Form 4 filing reveals that Yadin Rozov, a Director at Core Scientific, Inc., has acquired 110,000 shares of the company's common stock.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, sold 50,000 shares of common stock on May 27, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Todd M. DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., received a grant of 194,600 shares of common stock on April 28, 2025.

Core Scientific's CEO, Adam Sullivan, was granted 665,985 restricted stock units (RSUs) on April 28, 2025, according to a Form 4 filing.

Core Scientific's CEO, Adam Taylor Sullivan, sold 22,629 shares of common stock on April 1, 2025, to satisfy tax obligations related to vesting restricted stock units.

Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, sold 7,921 shares of common stock on April 1, 2025, to satisfy tax obligations related to vesting restricted stock units.

James P. Nygaard Jr., EVP and CFO of Core Scientific, Inc., reports acquiring 819,672 shares of common stock through a restricted stock unit grant.

Director Eric Stanton Weiss of Core Scientific, Inc. purchased 6,000 shares of common stock at a price of $8.4584 on March 6, 2025.

Director Jordan Levy purchased 62,500 shares of Core Scientific, Inc. common stock at a weighted average price of $8.0081 on March 6, 2025.

Director Todd A. Becker of Core Scientific, Inc. executed multiple sales of common stock and warrants on March 3rd and 4th, 2025.

Core Scientific director Eric Stanton Weiss acquired 20,448 shares of common stock through a restricted stock unit grant.

Director Jarrod M. Patten of Core Scientific, Inc. acquired 20,448 shares of common stock through a restricted stock unit grant.

Director Yadin Rozov of Core Scientific, Inc. acquired 20,448 shares through a restricted stock unit grant.

Director Jordan Levy of Core Scientific, Inc. acquired 20,448 shares of common stock through a restricted stock unit grant.

Core Scientific director Jeffrey David Booth acquired 20,448 shares through a restricted stock unit grant, which will vest on January 27, 2026.

Core Scientific director Todd Becker acquired 20,448 shares of common stock through a restricted stock unit grant that will vest on January 27, 2026.

Core Scientific's CEO, Adam Sullivan, sold 369,712 shares of common stock on January 24, 2025, to satisfy tax obligations related to vesting restricted stock units.

Todd M. Duchene, Chief Legal and Administrative Officer of Core Scientific, sold 25,277 shares of common stock on January 24, 2025, to satisfy tax obligations related to vesting restricted stock units.

Core Scientific's Chief Financial Officer, Denise Marie Brucia, sold 802 shares of common stock to cover tax obligations related to vesting restricted stock units.

Core Scientific's CEO, Adam Sullivan, acquired 159,306 shares through vesting of restricted stock units and sold 88,380 shares to cover tax obligations.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, acquired shares through vesting of restricted stock units and subsequently sold a portion to cover tax obligations.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, reports the acquisition and disposal of common stock and warrants.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, acquired 196,977 shares and warrants at a nominal price, while also disposing of 1,858,451 shares.

A director of Core Scientific, Inc. sold 105,000 shares of common stock at an average price of $18.1138 per share on November 22, 2024.